PPD Named �Best Vaccine CRO of the Year� in Asia-Pacific

WILMINGTON, N.C.–(BUSINESS WIRE)–PPD, Inc. (Nasdaq: PPD) was named �Best Vaccine CRO of the Year” at the Asia-Pacific Vaccine Excellence Awards 2021 for its strong presence, extensive experience and quality delivery in the Asia-Pacific (APAC) region.

The award recognizes the contract research organization (CRO) operating within Asia that has engaged in substantial efforts to innovate, optimize processes and uphold a high level of efficacy, quality and safety in vaccine development and manufacturing.

PPD accepted the award during a virtual ceremony at the third annual Vaccine World Asia Congress 2021, which attracted hundreds of representatives from Asia’s top vaccine and supply chain companies.

“This vaccine award further exemplifies PPD’s commitment to provide effective site management and ensure quality delivery, which has contributed to our industry reputation as a global leader,” said Les Enterline, senior vice president, global therapeutic unit head, vaccines. “We continue to leverage technology and implement best practices to help our customers move vaccines forward. PPD’s extensive pandemic experience also has assisted in developing leading approaches to help accelerate COVID-19 vaccines?.”

The Vaccine World Asia Congress is a vaccine-focused platform in Asia that brings together global partners and regional stakeholders to leverage partnership opportunities, discuss technological advancements and spearhead scientific innovation.

PPD continues to expand in APAC to serve local and global customers, with operations across the region. PPD provides a broad range of Phase I-IV services in APAC, including clinical monitoring, project management, regulatory affairs, pharmacovigilance, data management and patient recruitment.

Earlier this year, PPD opened its new multipurpose laboratory in Suzhou, China, to support Western and China-based pharmaceutical and biotech companies managing China research studies. The 67,000-square-foot facility in the Suzhou New District, Jiangsu Province, offers bioanalytical, biomarker and vaccine laboratory services to support discovery research and clinical trials across all phases of pharmaceutical development. The lab also supplements the company’s Shanghai central lab, which was established in 2015.

About PPD

PPD is a leading global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services. Our customers and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With more than 30,000 professionals worldwide, PPD has conducted clinical trials in more than 100 countries to help customers deliver life-changing therapies to improve health. We apply innovative technologies, therapeutic expertise and a firm commitment to quality to bend the cost and time curve of drug development and optimize value. For more information, visit www.ppd.com.

This news release contains forward-looking statements. These statements often include words such as “expect,” “believe,” “project,” “forecast,” “estimate,” “target” and other similar expressions. Although we believe these forward-looking statements are based on reasonable assumptions at the time they are made, you should be aware that many factors could affect our actual financial results, and therefore actual results might differ materially from those expressed in the forward-looking statements. Factors that might materially affect such forward-looking statements include, but are not limited to, the fragmented and highly competitive nature of the drug development services industry; changes in trends in the biopharmaceutical industry; our ability to keep pace with rapid technological changes that could make our services less competitive or obsolete; political, economic and/or regulatory influences and changes; the risks related to the proposed merger of PPD by Thermo Fisher Scientific Inc.; and other factors disclosed under the “Risk Factors” section in our periodic reports filed with the Securities and Exchange Commission (SEC), including our latest Annual Report on Form 10-K and Quarterly Report on form 10-Q, which are available on our website at https://investors.ppd.com or the SEC’s website at www.sec.gov. We assume no obligation and disclaim any duty to revise or update any forward-looking statements, or make any new forward-looking statement, whether as a result of new information, future events or otherwise, except as required by applicable law.

Contacts

PPD Contacts
Media:

Randy Buckwalter

+1 919 456 4425

media@ppd.com

Investors:

Tracy Krumme

+1 910 558 4186

investors@ppd.com